<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853047</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol LX1606.1-202-CS</org_study_id>
    <secondary_id>LX1606.202</secondary_id>
    <secondary_id>LX1032</secondary_id>
    <nct_id>NCT00853047</nct_id>
  </id_info>
  <brief_title>Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of LX1606 versus a
      placebo control in subjects with symptomatic carcinoid syndrome not managed by stable-dose
      long-acting octreotide therapy. Following determination of the maximally tolerated or
      effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (physical examinations, clinical laboratory tests, vitals signs measurements, and ECGs)</measure>
    <time_frame>Weekly and biweekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom diary</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (number of bowel movements compared to baseline)</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective global assessment</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on biomarker levels in blood (5-HT)</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on biomarker levels in urine (5-HIAA)</measure>
    <time_frame>Biweekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chromogranin-A levels in blood</measure>
    <time_frame>Biweekly</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Carcinoid Syndrome</condition>
  <arm_group>
    <arm_group_label>Low Dose LX1606 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of LX1606; daily oral intake for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Low Dose LX1606 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mid-low dose of LX1606; daily oral intake for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-High Dose LX1606 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mid-high dose of LX1606; daily oral intake for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose LX1606 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of LX1606; daily oral intake for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 LX1606 Expanded Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of LX1606 to an expanded cohort based upon Part 1; daily oral intake for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LX1606 Open Label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose LX1606 Part 1</intervention_name>
    <description>A low dose of LX1606; daily oral intake for 28 days</description>
    <arm_group_label>Low Dose LX1606 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid-Low Dose LX1606 Part 1</intervention_name>
    <description>A mid-low dose of LX1606; daily oral intake for 28 days</description>
    <arm_group_label>Mid-Low Dose LX1606 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid-High Dose LX1606 Part 1</intervention_name>
    <description>A mid-high dose of LX1606; daily oral intake for 28 days</description>
    <arm_group_label>Mid-High Dose LX1606 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose LX1606 Part 1</intervention_name>
    <description>A high dose of LX1606; daily oral intake for 28 days</description>
    <arm_group_label>High Dose LX1606 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 LX1606 Expanded Cohort</intervention_name>
    <description>A dose of LX1606 to an expanded cohort based upon Part 1; daily oral intake for 28 days</description>
    <arm_group_label>Part 2 LX1606 Expanded Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo dosing with daily oral intake for 28 days</description>
    <arm_group_label>Low Dose LX1606 Part 1</arm_group_label>
    <arm_group_label>Mid-Low Dose LX1606 Part 1</arm_group_label>
    <arm_group_label>Mid-High Dose LX1606 Part 1</arm_group_label>
    <arm_group_label>High Dose LX1606 Part 1</arm_group_label>
    <arm_group_label>Part 2 LX1606 Expanded Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX1606 Open Label Dose Extension</intervention_name>
    <description>Patients can enter an eight-week extension period at current dose based upon qualification.</description>
    <arm_group_label>LX1606 Open Label Extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX1606 Open Label Extension 2</intervention_name>
    <description>Patients can enter a 24-week extension period at current dose after the 8-week open-label extension period.</description>
    <arm_group_label>LX1606 Open Label Extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX1606 Open Label Extension 3</intervention_name>
    <description>Patients can enter a 48-week extension period at current dose after the 8-week open-label extension period and the 24-week open-label extension period.</description>
    <arm_group_label>LX1606 Open Label Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, aged 18 and older

          -  Biopsy-proven metastatic carcinoid tumor of the GI tract with disease extent confirmed
             by CT, MRI, or radionuclide imaging

          -  Symptoms not managed by stable-dose long-acting octreotide therapy (≥4 bowel movements
             per day)

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  ≥12 high volume, watery bowel movements per day

          -  Sponsor-unacceptable clinical laboratory values for hematology and liver function
             tests at screening

          -  Karnofsky status ≤70% - unable to care for self

          -  Surgery within 60 days prior to screening

          -  A history of short bowel syndrome

          -  Life expectancy &lt;12 months

          -  History of substance or alcohol abuse within 2 years prior to screening

          -  Previous exposure to a tryptophan hydroxylase (TPH) inhibitor

          -  Administration of any investigational drug within 30 days of screening or any
             therapeutic protein or antibody within 90 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo LaPuerta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Oncology Services of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Group Oncology and Hematology Specialists</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Weslaco</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <disposition_first_submitted>February 4, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 4, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 3, 2016</disposition_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 27, 2017</submitted>
    <returned>May 5, 2017</returned>
    <submitted>March 5, 2018</submitted>
    <returned>April 2, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

